Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 1:15 AM
Ignite Modification Date: 2025-12-25 @ 1:15 AM
NCT ID: NCT05662293
Eligibility Criteria: Prospective part Inclusion Criteria: * Diagnostic or suspicion of AiCM as presence of specified keyword in patient's file or as screened by colleagues of the internal medicine or cardiology clinics * Signed study consent Exclusion Criteria: * Patient's active refusal of the general consent of the University Hospital Basel * Age \<18 years old * Temporary exclusion criteria: Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (\>100 bpm, \<90 systolic BP, evidence of organ dysfunction). * Life expectancy \<1 year (palliative, terminal cancer) Retrospective part Inclusion Criteria: * Patients with a reduced left-ventricular ejection fraction (LVEF ≤50%) or a reduction of 15% in the ejection fraction (EF) between two echocardiographies and a concomitant diagnosis of any arrhythmia likely to lead to AiCM within one year before or after diagnosis of the reduced LVEF from 2010-2021 Exclusion Criteria: * Age \< 18 years old * Patient's active refusal of the general consent of the University Hospital Basel * Acute event clearly leading to an acutely reduced LVEF (massive type I myocardial infarction, cardiogenic shock from a coronary or myocardial etiology, septic shock leading to toxic myopathy, hypovolemic shock with reduced EF, cardiac arrest and/or need for resuscitation). * Patients with life expectancy \<1 year (palliative, terminal cancer)
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT05662293
Study Brief:
Protocol Section: NCT05662293